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Objective: There is increasing evidence that the addition of O-linked N-acetylglucosamine (O-GlcNAc) to
proteins plays an important role in cell signaling pathways. In chondrocytes, accumulation of O-GlcNAc-
modiﬁed proteins induces hypertrophic differentiation. Osteoarthritis (OA) is characterized by cartilage
degradation, and hypertrophic-like changes in hyaline chondrocytes. However, the mechanisms
responsible for these changes have not been described. Our aim was to study whether O-GlcNAcylation
and the enzymes responsible for this modiﬁcation are dysregulated in the cartilage of patients with knee
OA and whether interleukin-1 could induce these modiﬁcations in cultured human OA chondrocytes
(HOC).
Design: Human cartilage was obtained from patients with knee OA and from age and sex-matched
healthy donors. HOC were cultured and stimulated with the catabolic cytokine IL-1a. Global protein
O-GlcNAcylation and the synthesis of the key enzymes responsible for this modiﬁcation, O-GlcNAc
transferase (OGT) and O-GlcNAcase (OGA), were assessed by western blot.
Results: OA was associated with a 4-fold increase in the global O-GlcNAcylation in the cartilage. OA
cartilage showed a re-distribution of the OGT and OGA isoforms, with a net increase in the presence
of both enzymes, in comparison to healthy cartilage. In HOC, IL-1a stimulation rapidly increased
O-GlcNAcylation and OGT and OGA synthesis.
Conclusions: Our results indicate that a proinﬂammatory milieu could favor the accumulation of
O-GlcNAcylated proteins in OA cartilage, together with the dysregulation of the enzymes responsible
for this modiﬁcation. The increase in O-GlcNAcylation could be responsible, at least partially, for the
re-expression of hypertrophic differentiation markers that have been observed in OA.
 2013 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Osteoarthritis (OA) is recognized as a whole organ disease
mainly characterized by the gradual loss of articular cartilage.
Although alternative routes have been proposed, research has
focused on the change in chondrocyte metabolism that leads to
cartilage degradation. It has been proposed that during OA, artic-
ular chondrocytes lose their quiescent surrounding, characterized
by type II collagen (colII) and aggrecan, and regain a behavior with
similarities to hypertrophic chondrocytes in the growth plate ofo: R. Largo, Bone and Joint




s Research Society International. Pgrowing individuals, although this is controversial1,2. Several
studies have demonstrated that different markers of chondrocyte
hypertrophy, such as colX, matrix metalloproteinase 13 (MMP13),
Indian Hedgehog (IHH), Runx-2, osteocalcin, osteopontin or alka-
line phosphatase (ALP), are increased in OA cartilage, at least in
certain subsets of patients, or in different stages of the disease1,2.
The ultimate end stage of chondrocyte hypertrophy in the growth
plate is calcium deposition, allowing bone to enlarge. Although
calciﬁcation does not have to be unavoidably reached in OA carti-
lage, tidemark duplication and an increase in calciﬁed cartilage
thickness are frequently observed.
The addition of the single-sugar N-acetylglucosamine (O-
GlcNAc) by O-linkage (O-linked b-N-acetyl-glycosylation, O-
GlcNAcylation) to nuclear, mitochondrial and cytoplasmic proteins
is a form of protein glycosylation that has emerged as an important
regulatory mechanism for numerous cellular processes3,4. Overublished by Elsevier Ltd. All rights reserved.
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almost every functional class of proteins, including transcription
factors, cytoskeletal proteins, RNA polymerases, cell cycle regula-
tors, phosphatases and kinases are known to be O-GlcNAcylated3,4.
Analogous to phosphorylation, this dynamic and reversible process
of post-translational modiﬁcation is responsive to a great variety of
stimuli, including stress and nutrient metabolism3e5. The attach-
ment of the sugar is controlled by two highly conserved enzymes,
the O-GlcNAc transferase (OGT) and by the neutral N-acetylgluco-
saminidase O-GlcNAcase (OGA), that catalyzes the hydrolytic
cleavage of O-GlcNAc form proteins4,5. The donor substrate for the
reaction, UDP-GlcNAc, is synthesized by the hexosamine biosyn-
thesis pathway (HBP), amajor branch of the glycolytic pathway that
metabolizes 2e5% of cell glucose, that is also sensitive to many
metabolic routes3.
The alteration in protein O-GlcNAcylation has been described to
have a pathogenic role in various chronic and age related human
diseases including diabetes mellitus, cardiovascular disease, neu-
rodegeneration and cancer3e5. Despite the importance described
for O-GlcNAcylation in degenerative and age related diseases, its
role in OA is completely unknown. We have recently reported that
O-GlcNAcylation is increased during the hypertrophic differentia-
tion of chondrocytes6. Furthermore, the accumulation of O-
GlcNAcylated proteins per se was able to induce a signiﬁcant
expansion in the growth plate height in newborn mice, and the
hypertrophic differentiation of chondrocytes, increasing the gene
expression of colX, IHH, ALP or Runx-26. These markers are also
increased in human OA cartilage, although the mechanisms asso-
ciated to the induction of this phenotype have not been clearly
established.
The concentration of the proinﬂammatory and catabolic factor
interleukin-1a (IL-1a) is increased in OA joints. Furthermore, IL-1a is
able to induce an increase in thematrix degrading enzymes found in
the OA joint. Therefore, the aim of this work was to analyzewhether
O-GlcNAcylation and the presence of the different isoforms of OGT
and OGA, are modiﬁed in the articular cartilage from patients with
knee OA. We also studied whether the presence of IL-1a is able to
induce O-GlcNAcylation or to modify the presence of the regulating
enzymes, in cultured human OA chondrocytes (HOC).
Materials and methods
Human articular cartilage samples
OA knee articular cartilagewas obtained during the replacement
surgery (Orthopaedic Surgery Dept. Fundación Jimenez Díaz,
Madrid, Spain). Twelve OA patients were included in this study (six
women/six men; mean age 71  3 years; Mankin score between 11
and 14). Healthy human knee cartilage was obtained from ten do-
nors (four women/six men; mean age: 65  3 years; Mankin score
between 1 and 4) without a known history of joint disease
(Transplant Services Foundation, Hospital Clinic, Barcelona, Spain).
Informed consent was obtained from all individuals. The Medical
Ethics Committee of the Fundación Jiménez Díaz and Hospital
Clinic approved the protocol.
HOC for primary culture were isolated from the OA cartilage by
sequential digestion with pronase and collagenase. Chondrocyte
culture was characterized by safranin O and alcian-blue staining
and gene expression (type II and X collagen, aggrecan) (data not
shown). Chondrocytes were grown to conﬂuence in Dulbecco’s
Modiﬁed Eagle's Medium (DMEM) (4.5 g/L glucose; Lonza; Verv-
iers, Belgium) supplemented with 10% fetal calf serum (Lonza),
60 U/ml penicillin, 60 mg/ml streptomycin and 2 mmol/L glutamine
(Lonza) at 37C in the presence of 5% CO2. Experiments were per-
formed with ﬁrst or second passage cells. In each experiment, cellswere made quiescent for 48 h in DMEM medium without serum
and stimulated with 10 ng/ml IL-1a (Sigma Aldrich, St Louis, MO,
USA) for different periods of time.
Western blot
Proteins from human cartilage or HOC were isolated in ice-cold
lysis buffer [15 mM Hepes pH 7.4; 250 mM NaCl; 10% glycerol; 0.5%
NP-40; 0.5 mM Ethylene-diamine-tetraacetic acid (EDTA)] in the
presence of the speciﬁc protease inhibitors PMSF 0.1 mM (Phenyle
methylesulfonyleﬂuoride) and Protease Inhibitor Cocktail (both
from Sigma). The lysates were centrifuged at 12,000 g for 10 min
twice. Protein concentrations were determined by a colorimetric
method. Equal amounts of proteins were resolved on 8% acryl-
amideesodium docecyl sulphate (SDS) gels and transferred to
nitrocellulose membranes (Bio-Rad, Hercules, CA, USA). Western
blots were carried out as previously described employing anti-
bodies against O-GlcNAc-modiﬁed proteins (RL2: Thermo Fisher
Scientiﬁc, Waltham, CA, USA), OGT (DM17: Sigma, St. Louis, MO,
USA) and OGA 345 (kindly donated by Dr GW Hart, Johns Hopkins
University School of Medicine, Baltimore, USA)6. Bands were
quantiﬁed by densitometry and results expressed as arbitrary units
(Quantity One Software 4.6.3). For total O-GlcNAc quantiﬁcation, all
the immunoreactive bands were merged6.
Statistical analysis
Results are expressed as mean values with 95% conﬁdence in-
tervals. Comparisons between multiple groups were performed
using KruskaleWallis test and comparison of two groups were
analyzed using the ManneWhitney U test. A P value of less than
0.05 was considered statistically signiﬁcant.
Results
Quantiﬁcation of O-GlcNAcylated proteins in the cartilage
As can be observed in Fig. 1(A), OA cartilage showed around a 4-
fold increase in the amount of O-GlcNAcylated proteins in com-
parison to healthy cartilage, with the most extensive O-GlcNAcy-
lation observed in the areas of 45e70 and 120e170 kDa. There was
little O-GlcNAcylation of proteins of less than 40 kDa in size, or
higher than 170 kDa.
Synthesis of OGT and OGA in the human cartilage
In the human cartilage we identify all the three different OGT
isoforms that have been previously described as ncOGT (nuclear
and cytoplasmic OGT), mOGT (mitochondrial OGT) and sOGT (short
OGT)5. While ncOGT and mOGT were downregulated, we observed
a marked increase in sOGT in OA patients in comparison to healthy
cartilage [Fig. 1(B)]. Regarding OGA, both isoforms described in
humans were identiﬁed in the cartilage5,6. While the synthesis of
OGA-L, the full-length isoform, was found to be decreased in the
OA cartilage, there was a clear increase in the OGA-S isoform in
the OA cartilage in comparison to healthy one [Fig. 1(B)].
Alterations in the amount of O-GlcNAcylated proteins following IL-1
stimulation in HOC
To gain insight into the relationship between O-GlcNAcylation
and OA associated events in the cartilage, wemeasured the effect of
the catabolic cytokine IL-1a on HOC in culture. IL-1a treatment
resulted in an accumulation of O-GlcNAcylated proteins in HOC in a
time-dependent manner, with a peak of induction 6 h after
Fig. 1. O-GlcNAcylated protein levels and OGT and OGA presence in human healthy (white dots) and OA (black dots) knee cartilage. (A) Representative western blot and densi-
tometric analysis for O-GlcNAcylated protein measurement using RL2 antibody. (B) Representative western blot and densitometric analysis for the three OGT isoforms, nucleo-
cytoplasmic (ncOGT), mitochondrial (mOGT) and small (sOGT); and the two OGA isoforms, long (OGA-L) and short (OGA-S). EZ blue staining was used as protein loading con-
trols. Results are expressed as fold induction for each patient, and the mean  95% C.I. n ¼ 10 healthy and n ¼ 12 OA subjects; P values calculated by ManneWhitney test.
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of all three OGT isoforms as early as 3 h, although the peak of in-
duction was at 6 h. IL-1a also increased the presence of OGA-S
isoforms after 3 and 6 h of stimuli [Fig. 2(B)].
Discussion
O-GlcNAcylation has been described as a key regulator of cell/
tissue function. Thousands of proteins, such as chromatin-
associated proteins, transcription factors, proteasomal proteins,
cytoskeletal proteins, kinases or metabolic enzymes, are O-
GlcNAcylated. Here, we have described that in human OA cartilage
there is an accumulation of O-GlcNAcylated proteins associated to
an alteration in the expression of the enzymes that regulate this
glycosylation. To our knowledge, this is the ﬁrst description of an
activation of protein O-GlcNAcylation in the cartilage associated to
a human joint pathology. However, we recently described that O-GlcNAcylation has a chondromodulating activity because it was
able to increase the expression of hypertrophic differentiation
markers in chondrocytes6. Pathological chondrocyte hypertrophy is
observed in OA associated with the re-emergence of a “develop-
mental” pattern of gene and protein expression in the cartilage2.
Interestingly, we observed that protein O-GlcNAcylation accumu-
lation in cultured chondrocytes preceded the increase in the gene
expression of hypertrophic markers6. Furthermore, O-GlcNAcyla-
tion per se was able to induce chondrocyte hypertrophy6. So, the
increased O-GlcNAcylation observed in the cartilage of OA patients
could account, at least partially, for the increased expression of
hypertrophic markers that have been described in OA cartilage.
Chronic increases in O-GlcNAcylation have also been associated to
cell hypertrophy in renal and cardiac cells7,8, that is characterized
by cell cycle arrest and the inhibition of cell proliferation. An in-
crease in local O-GlcNAcylation has been described during human
cardiac hypertrophy, together with a dysregulation of OGT and OGA
Fig. 2. (A) O-GlcNAcylated protein levels and (B) OGT and OGA presence in HOC stimulated with IL-1a for different periods up to 24 h. Representative western blot and densitometric
analysis for O-GlcNAcylated protein detection using RL2 antibody the three OGT isoforms, nucleo-cytoplasmic (ncOGT), mitochondrial (mOGT) and small (sOGT), and the two OGA
isoforms, long (OGA-L) and short (OGA-S). Results are shown as fold change vs 0 h  95% C.I. of four independent experiments. P values calculated by ManneWhitney test vs Basal.
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with cardiomyocyte hypertrophy was also concomitant with an
increase in O-GlcNAcylation8. Regarding kidney cells, the hyper-
trophy of mesangial cells was associated to an increase in protein O-
GlcNAcylation both in patients and in cells in culture9.
A chronic dysregulation in the level of protein O-GlcNAcylation
has been described in different chronic human pathologies,
including diabetes, cardiomyopathy, vascular dysfunction, diabetic
nephropathy or cancer3e5,9. The contribution of this type of
glycosylation to the etiology of these diseases has been especially
underlined in diabetes and diabetic complications, where the in-
crease in O-GlcNAcylation has been proposed, at least partially, as
the cause for the toxic effects of glucose10. Different genetic orenzymatic manipulations that increased O-GlcNAc were able to
induce insulin resistance or hyperleptinemia10, suggesting a direct
role in the induction of the disease. In experimental models of
diabetes, excessive O-GlcNAcylation preceded histologic and func-
tional alterations in diabetic cardiomyopathy11. Furthermore,
reducing the level of O-GlcNAc, reversed some of the complications
associated to this disease5. So, a chronic increase in O-GlcNAcyla-
tion seems to be associated to the toxic effects of glucose or to an
impairment in the management of nutrients/energy. OA has also
been associated to a dysregulation in glucose and ATP metabolism
in the chondrocyte. HOC showed an altered ability to regulate
glucose entry in the cell12,13, together with a reduced activity of
the mitochondrial electron transport complexes14. An increase in
L. Tardio et al. / Osteoarthritis and Cartilage 22 (2014) 259e263 263O-GlcNAcylation in OA cartilage could be probably responsible for
the reduced activity of thesemitochondrial complexes demonstrated
in HOC. The increase in O-GlcNAcylation observed in OA cartilage
was associated with a re-distribution of the expression of OGT iso-
forms, with a net increase in OGT. Increased expression of OGT has
been associated with O-GlcNAc accumulation both in response to
acute stress and chronic damage5. We also observed an increase in
OGA expression, the enzyme which removes O-GlcNAc, in the OA
cartilage. In HOC, O-GlcNAc accumulation paralleled an increase in
both OGT and OGA. Our results are consistent with recently pub-
lished data, suggesting that OGT and OGA may increase or decrease
in tandem in response to a modiﬁcation in O-GlcNAc levels5,6.
We have also observed that IL-1, a key catabolic cytokine in OA,
is able to induce O-GlcNAc accumulation in HOC. Recent data have
also implicated global and speciﬁc sites of O-GlcNAcylation in the
inﬂammatory response induced by IL-115. Our data indicate that IL-
1 is able to induce the modiﬁcation of the O-GlcNAc system in the
cartilage thus supporting the relationship between OA and O-
GlcNAc levels.
In conclusion, these results demonstrate that there is a dysre-
gulation of O-GlcNAcylation of cartilage proteins during human OA
together with changes in the expression of OGT and OGA isoforms
that could be probably induced by proinﬂammatory cytokines. O-
GlcNAc accumulation could be responsible, at least partially, for the
re-expression of hypertrophic differentiation markers that have
been observed in OA cartilage. Our data would link OA patho-
physiology to alterations in key glucose sensor pathways, and
support the hypothesis that O-GlcNAcylation may play an impor-
tant role in the development of chronic and age-related diseases.
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